Compare Gilead Sciences, Inc. (GILD) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nano Dimension Ltd - ADR — how do they compare? Gilead Sciences, Inc. trades at $135.36 (market cap $163.51B), while Nano Dimension Ltd - ADR trades at $1.48 (market cap $312.60M). The key difference: Gilead Sciences, Inc. is far larger — about 523.1× Nano Dimension Ltd - ADR's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| GILD | NNDM | |
|---|---|---|
Market Cap | $163.51B | $312.60M |
Sector | Health | Technology |
52-Week High | $155.80 | $2.14 |
52-Week Low | $108.22 | $1.21 |
Enterprise Value | $178.05B | -$96.74M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Nano Dimension (NNDM) trades at $1.49, down 0.67% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue growth but continues to post significant losses, with a net income margin of -286.72% and negative cash flow from operations of -$101.28M. Recent news highlights boardroom disputes with shareholder Murchinson and a proposed business combination with Infinite Epigenetics, creating uncertainty around strategic direction.
The outlook remains challenged by persistent cash burn and lack of profitability despite revenue increases. Investment opportunity lies in the company's cash position of $757.96M and low P/B ratio of 0.64, but risks include ongoing operational losses, shareholder activism, and execution risks in strategic initiatives. The stock faces headwinds from negative investor sentiment and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
